MoonLake Immunotherapeutics (MLTX)
46.48
-0.28
(-0.60%)
USD |
NASDAQ |
Nov 04, 16:00
46.48
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value: 2.430B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 2.430B |
| October 31, 2024 | 2.409B |
| October 30, 2024 | 2.445B |
| October 29, 2024 | 2.520B |
| October 28, 2024 | 2.511B |
| October 25, 2024 | 2.426B |
| October 24, 2024 | 2.395B |
| October 23, 2024 | 2.420B |
| October 22, 2024 | 2.508B |
| October 21, 2024 | 2.572B |
| October 18, 2024 | 2.567B |
| October 17, 2024 | 2.513B |
| October 16, 2024 | 2.579B |
| October 15, 2024 | 2.508B |
| October 14, 2024 | 2.565B |
| October 11, 2024 | 2.567B |
| October 10, 2024 | 2.445B |
| October 09, 2024 | 2.489B |
| October 08, 2024 | 2.625B |
| October 07, 2024 | 2.743B |
| October 04, 2024 | 2.966B |
| October 03, 2024 | 2.760B |
| October 02, 2024 | 2.748B |
| October 01, 2024 | 2.742B |
| September 30, 2024 | 2.660B |
| Date | Value |
|---|---|
| September 27, 2024 | 2.596B |
| September 26, 2024 | 2.720B |
| September 25, 2024 | 2.685B |
| September 24, 2024 | 2.902B |
| September 23, 2024 | 2.974B |
| September 20, 2024 | 2.888B |
| September 19, 2024 | 2.867B |
| September 18, 2024 | 2.830B |
| September 17, 2024 | 2.696B |
| September 16, 2024 | 2.633B |
| September 13, 2024 | 2.706B |
| September 12, 2024 | 2.699B |
| September 11, 2024 | 2.409B |
| September 10, 2024 | 2.420B |
| September 09, 2024 | 2.430B |
| September 06, 2024 | 2.384B |
| September 05, 2024 | 2.356B |
| September 04, 2024 | 2.471B |
| September 03, 2024 | 2.402B |
| August 30, 2024 | 2.432B |
| August 29, 2024 | 2.476B |
| August 28, 2024 | 2.433B |
| August 27, 2024 | 2.440B |
| August 26, 2024 | 2.518B |
| August 23, 2024 | 2.620B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
132.19M
Minimum
Jun 30 2022
3.368B
Maximum
Feb 12 2024
1.527B
Average
1.986B
Median
Enterprise Value Benchmarks
| Novartis AG | 235.04B |
| AC Immune SA | 102.01M |
| CRISPR Therapeutics AG | 3.839B |
| Addex Therapeutics Ltd | 7.218M |
| NLS Pharmaceutics Ltd | 14.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.27M |
| Total Expenses (Quarterly) | 30.58M |
| EPS Diluted (Quarterly) | -0.39 |
| Earnings Yield | -1.91% |